CYTOXAN SUMMARY
CYTOXAN®
(cyclophosphamide for injection, USP)
CYTOXAN® Tablets
(cyclophosphamide tablets, USP)
CYTOXAN® (cyclophosphamide for injection, USP) is a sterile white powder containing cyclophosphamide monohydrate. CYTOXAN Tablets (cyclophosphamide tablets, USP) are for oral use and contain 25 mg or 50 mg cyclophosphamide (anhydrous). Cyclophosphamide is a synthetic antineoplastic drug chemically related to the nitrogen mustards.
CYTOXAN is indicated for the following:
Malignant Diseases
CYTOXAN, although effective alone in susceptible malignancies, is more frequently used concurrently or sequentially with other antineoplastic drugs. The following malignancies are often susceptible to CYTOXAN treatment:
- Malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin’s disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma.
- Multiple myeloma.
- Leukemias: Chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia in children (CYTOXAN given during remission is effective in prolonging its duration).
- Mycosis fungoides (advanced disease).
- Neuroblastoma (disseminated disease).
- Adenocarcinoma of the ovary.
- Retinoblastoma.
- Carcinoma of the breast.
Biopsy Proven “Minimal Change” Nephrotic Syndrome in Children
CYTOXAN is useful in carefully selected cases of biopsy proven “minimal change” nephrotic syndrome in children but should not be used as primary therapy. In children whose disease fails to respond adequately to appropriate adrenocorticosteroid therapy or in whom the adrenocorticosteroid therapy produces or threatens to produce intolerable side effects, CYTOXAN may induce a remission. CYTOXAN is not indicated for the nephrotic syndrome in adults or for any other renal disease.
|
CYTOXAN NEWS HIGHLIGHTS
Media Articles Related to Cytoxan (Cyclophosphamide)
Ovarian Function Preserved In Women With Severe Systemic Lupus Erythematosus When Treated With Cyclophosphamide And Mycophenolate Mofetil
Source: Lupus News From Medical News Today [2008.06.13]
Phase III Study Showed Rituxan Combined With Chemotherapy Improved Progression-Free Survival In Patients With Relapsed Chronic Lymphocytic Leukemia
Source: Blood / Hematology News From Medical News Today [2008.10.07]
Rituximab Improves Symptoms of Rheumatoid Arthritis
Source: Medscape Pharmacotherapy Headlines [2004.06.16]
Published Studies Related to Cytoxan (Cyclophosphamide)
Efficacy of intravenous pulse cyclophosphamide treatment versus combination of intravenous dexamethasone and oral cyclophosphamide treatment in steroid-resistant nephrotic syndrome. [2008.09]
Cyclosporin A is superior to cyclophosphamide in children with steroid-resistant nephrotic syndrome-a randomized controlled multicentre trial by the Arbeitsgemeinschaft fur Padiatrische Nephrologie. [2008.09]
Efficacy of intravenous pulse cyclophosphamide treatment versus combination of intravenous dexamethasone and oral cyclophosphamide treatment in steroid-resistant nephrotic syndrome. [2008.06.20]
Randomized phase 3 trial of Fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer. [2008.06.04]
A randomized phase-III trial of docetaxel/capecitabine versus doxorubicin/cyclophosphamide as primary chemotherapy for patients with stage II/III breast cancer. [2008.06]
Clinical Trials Related to Cytoxan (Cyclophosphamide)
Phase III Comparison of Adjuvant Chemotherapy W/High-Dose Cyclophosphamide Plus Doxorubicin (AC) vs Sequential Doxorubicin Fol by Cyclophosphamide (A-C) in High Risk Breast Cancer Patients With 0-3 Positive Nodes (Intergroup, CALGB 9394) [Active, not recruiting]
High-Dose Intravenous (IV) Cyclophosphamide Versus Monthly IV Cyclophosphamide [Active, not recruiting]
Cytoxan, Epirubicin and Capecitabine in Women With Breast Cancer [Active, not recruiting]
A Study of ZYC300 Administered With Cyclophosphamide Pre-Dosing [Active, not recruiting]
A Three Arm Study of Adriamycin, Cyclophosphamide Plus Docetaxel vs Adriamycin Plus Cyclophosphamide Followed By Paclitaxel vs Adriamycin Plus Cyclophosphamide Followed By Paclitaxel and Gemcitabine in Adjuvant Breast Cancer [Active, not recruiting]
|
